Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction

Insurance struggles to cover precision cancer drugs like Lynparza, costing $8,700/month out of pocket. Novo invests $18M in childhood obesity prevention with UNICEF. Roche's obesity drug enicepatide shows 15.5% weight loss in trials. Big Pharma faces $400B revenue risk from patent expirations by 2033. Healthcare workers face rising insurance costs, with ACA premiums reaching $1,600/month in Idaho.

Florida AG James Uthmeier sued Eli Lilly, Novo Nordisk, Sanofi, CVS Caremark, Express Scripts, OptumRx, and rebate aggregators, alleging a scheme to inflate insulin prices. The complaint claims manufacturers raised list prices and paid rebates to pharmacy benefit managers for preferred formulary placement, leaving patients to pay higher costs. Florida has 2.3 million diabetic adults, many relying on insulin.

Florida Attorney General James Uthmeier filed a lawsuit against Eli Lilly, Novo Nordisk, Sanofi, and three PBMs, accusing them of price-fixing and anti-competitive behavior in insulin and diabetes-related drugs. The lawsuit seeks damages and injunctions under Florida's trade and antitrust laws.

Novo Nordisk (NVO) shares dropped 7% to $39.82 after presenting long-term targets that did not alleviate investor concerns about competition in the weight-loss drug market. The company aims to launch over five multi-blockbuster drugs by 2030 and generate $23B in pipeline sales by 2035. CEO Mike Doustdar acknowledged patent exclusivity loss for semaglutide in the early 2030s, which drives 75% of 2026 sales.

Florida sued Eli Lilly, Sanofi, Novo Nordisk, CVS, and others in an antitrust case. The state alleges collusion to inflate insulin and weight-loss drug prices. The lawsuit claims rebates were exchanged for preferred formulary placement.

Hundreds of lawsuits allege that GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, may increase the risk of NAION, a rare form of vision loss. Novo Nordisk and Eli Lilly dispute these claims, citing research showing no increased risk. Studies have shown a modest increase in NAION risk with semaglutide, but the FDA has not issued a safety warning.